Detailed narrative
Bioprocessing equipment order inflection
Bioprocessing core grew high single digits, led by high-single-digit consumables growth on robust commercialized-therapy demand, notably in China. Equipment declined modestly, but orders grew more than 30% YoY — the first YoY equipment order growth in nearly 2 years. Management attributes the recovery to two years of industry underinvestment in capacity against robust consumables activity, plus a reshoring dynamic; brownfield projects are moving now with larger greenfield investments expected to follow.
Management frames this as the early stages of a multiyear investment cycle, though equipment revenue timing remains lumpy and gated by customer readiness.
China recovery across Biotechnology and Life Sciences
China core revenue grew mid-single digits, as better-than-expected Biotechnology and Life Sciences growth more than offset an expected high-single-digit Diagnostics decline from volume-based procurement and reimbursement policy changes. Bioprocessing in China grew double digits, with the biotech market accelerating as therapy monetization improved through multinational licensing deals and reopened IPO/stock-exchange access.
Diagnostics VBP headwinds ($75M-$100M full-year) played out as expected, but China patient volumes ran slightly higher — an encouraging demand indicator as the largest YoY policy impacts pass.
Diagnostics: respiratory drag masks strong core
Diagnostics core revenue declined 4%, dragged by a lighter respiratory season — Cepheid respiratory fell ~25% YoY. Underneath, clinical diagnostics grew low single digits (mid-single digits ex-China) and Beckman Coulter delivered mid-single-digit growth outside China led by immunoassay reagents and instrumentation.
Cepheid's core non-respiratory menu grew mid-teens, with sexual-health and hospital-acquired-infection assays up 20%. Momentum for the recently cleared Xpert GI panel supports the multiplexing installed-base strategy.
Masimo acquisition and capital deployment
Danaher is acquiring Masimo, a pulse-oximetry and patient-monitoring leader in acute care, announced in February and pending regulatory approval with close expected later this year. Management frames it as a typical Danaher deal extending the Radiometer acute-care strategy, accretive at growth, gross-margin and operating-margin levels, with $125M cost and ~$50M revenue synergies by year 5 and high-single-digit ROIC by year 5.
Post-close leverage of ~2.5 turns is expected to de-lever quickly on >$5B annual FCF, keeping the M&A funnel active across all three segments.
AI as a multi-year demand accelerator
Management argued AI is a near- and long-term tailwind that accelerates the drug development and commercialization flywheel, lifting the ~10%+ industry pipeline yield. Near term, 'autonomous science' — building biologic models — drives incremental demand for automation, analytical instruments and reagents, an area where Danaher is well represented; these biologic models require far more data than large language models, implying a multi-year driver.
Longer term, compressed development cycle times and higher hit rates expand commercial drug manufacturing (bioprocessing) and demand for near-personalized diagnostics. Internally, management describes AI-enabled DBS and DBS-enabled AI as synonymous drivers of cycle-time and cost efficiency.
Cost and margin execution
Gross margin was 60.3% and adjusted operating profit margin was 30.2%, up 60 bps YoY, as year-over-year cost savings more than offset the lower respiratory revenue. Adjusted EPS of $2.06 grew 9.5% and FCF of $1.1B converted at 105% of net income.
Management flagged oil-price-driven petrochemical/resin cost pressure from Middle East volatility as a watch item that has not yet been meaningful, mitigated via DBS and contract positions reviewed monthly across every operating company.